Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor - collagen interaction in baboons

Summary

Revascularization techniques, such as angioplasty and stent implantation, frequently lead to restenosis due to the formation of neointima after platelet activation and the concomittant release of various smooth muscle cell mitogenic and attractant factors. We here investigate whether inhibition of initial platelet adhesion after stent implantation can decrease neointima formation in a clinically relevant baboon model of in-stent stenosis using standard treatment with aspirin, clopidogrel and heparin. Inhibition of platelet adhesion was established by administration of the anti-von Willebrand factor (VWF) monoclonal antibody 82D6A3, which inhibits VWF binding to collagen. Administration of 82D6A3 resulted in a complete inhibition of VWF binding to collagen during the first three days after stent implantation. No thrombocytopenia or prolongation of the bleeding time was observed. Our results show that the formation of neointima was not affected in the group of baboons where primary platelet adhesion was abolished with 82D6A3 when compared to the control group. Vascular injury scores were the same in both groups. Inhibition of platelet adhesion during the first three days after stenting, on top of standard treatment with aspirin, clopidogrel and heparin, had no effect on neo-intima formation in a baboon model of in-stent stenosis. During the last decade, attempts to translate seemingly effective therapies based on smaller animal experimentation to the clinic have consistently failed. This study, using a non-human primate model that more closely resembles the clinical situation, presents a model that may be of further clinical interest for studying the prevention of restenosis.

Keywords

vonWillebrand factor - stenosis - baboon model - stent - neointima

^* S.F.D.M and S.S contributed equally to this manuscript.

• References

• 1 Bennett MR, O’Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacol Ther 2001; 91: 149-166.
• 2 Morice MC, Serruys PW, Sousa JE. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
• 3 Moses JW, Leon MB, Popma JJ. et al. Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
• 4 Stone GW, Ellis SG, Cox DA. et al. A polymerbased, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
• 5 Gallo R, Padurean A, Jayaraman T. et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164-2170.
• 6 Joner M, Finn AV, Farb A. et al. Pathology of drugeluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
• 7 Muldowney III JA, Stringham JR, Levy SE. et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 2007; 27: 400-406.
• 8 Steinhubl SR, Topol EJ. Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. J Thromb Thrombolysis 1999; 7: 227-231.
• 9 Bhatt DL, Bertrand ME, Berger PB. et al. Metaanalysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14.
• 10 Steinhubl SR, Berger PB, Mann III JT. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
• 11 Zahger D, Fishbein MC, Garfinkel LI. et al. VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Circulation 1995; 92: 1269-1273.
• 12 Topol EJ, Califf RM, Weisman HF. et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994; 343: 881-886.
• 13 Neumann FJ, Blasini R, Schmitt C. et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-2701.
• 14 Topol EJ, Mark DB, Lincoff AM. et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/ IIIa Inhibitor for Stenting. Lancet 1999; 354: 2019-2024.
• 15 Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study).. The ERASER Investigators. Circulation 1999; 100: 799-806.
• 16 Kastrati A, Mehilli J, Schuhlen H. et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-238.
• 17 Waissbluth A, Ghigliotti G, Abendschein DR. et al. Aurintricarboxylic acid attenuates intimal thickening after balloon injury of the rabbit aorta. Thromb Haemost 2002; 88: 668-672.
• 18 Matsuno H, Kozawa O, Niwa M. et al. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb Haemost 1998; 79: 865-871.
• 19 Kageyama S, Yamamoto H, Yoshimoto R. Antihuman von willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arterioscler Thromb Vasc Biol 2000; 20: 2303-2308.
• 20 Matsuno H, Kozawa O, Niwa M. et al. Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation 1997; 96: 1299-1304.
• 21 Cruz CP, Eidt J, Drouilhet J. et al. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg 2001; 34: 724-729.
• 22 Davis JA, Brown AT, Alshafie T. et al. Saratin (an inhibitor of platelet-collagen interaction) decreases platelet aggregation and homocysteine-mediated postcarotid endarterectomy intimal hyperplasia in a dosedependent manner. Am J Surg 2004; 188: 778-785.
• 23 Lafont A, Faxon D. Why do animal models of postangioplasty restenosis sometimes poorly predict the outcome of clinical trials?. Cardiovasc Res 1998; 39: 50-59.
• 24 Libby P, Tanaka H. The molecular bases of restenosis. Prog Cardiovasc Dis 1997; 40: 97-106.
• 25 Wu D, Vanhoorelbeke K, Cauwenberghs N. et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood 2002; 99: 3623-3628.
• 26 Staelens S, Hadders MA, Vauterin S. et al. Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain. J Biol Chem 2006; 281: 2225-2231.
• 27 Hoylaerts MF, Yamamoto H, Nuyts K. et al. von Willebrand factor binds to native collagen VI primarily via itsA1 domain. Biochem J 1997; 324 Pt 1 185-191.
• 28 Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest 1987; 47: 143-149.
• 29 Vanhoorelbeke K, Cauwenberghs N, Vauterin S. et al. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-113.
• 30 Schwartz RS, Huber KC, Murphy JG. et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19: 267-274.
• 31 Banai S, Gertz SD, Gavish L. et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc Res 2004; 64: 165-171.
• 32 Sinnaeve P, Chiche JD, Gillijns H. et al. Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation 2002; 105: 2911-2916.
• 33 Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc 2006; 81: 641-652.
• 34 Teirstein P, Reilly JP. Late stent thrombosis in brachytherapy: the role of long-term antiplatelet therapy. J Invasive Cardiol 2002; 14: 109-114.
• 35 Vanhoorelbeke K, Depraetere H, Romijn RAP. et al. A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal Anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction. J Biol Chem 2003; 278: 37815-37821.
• 36 Muller DW, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol 1992; 19: 418-432.
• 37 Goodnight SH. Aspirin therapy for cardiovascular disease. Curr Opin Hematol 1996; 3: 355-360.
• 38 Eriksson P. Reply: Long-term clopidogrel following PCI: marginal antithrombotic effects are offset by increased bleeding risks. Eur Heart J 2004; 25: 2170-2171.
• 39 Kandzari DE, Berger PB, Kastrati A. et al. Influence of treatment duration with a 60335-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44: 2133-2136.
• 40 Kinlough-Rathbone RL, Packham MA, Mustard JF. Vessel injury, platelet adherence, and platelet survival. Arteriosclerosis 1983; 3: 529-546.
• 41 Fuster V, Falk E, Fallon JT. et al. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost 1995; 74: 552-559.
• 42 Touchard AG, Schwartz RS. Preclinical restenosis models: challenges and successes. Toxicol Pathol 2006; 34: 11-18.
• 43 Phillips MD, Moake JL, Nolasco L. et al. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets. Blood 1988; 72: 1898-1903.
• 44 Cruz CP, Eidt J, Drouilhet J. et al. Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg 2001; 34: 724-729.